Biosenic
BIOS
Company Profile
Business description
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.
Contact
Rue Granbonpre 11
Batiment H (bte 24)
Mont-St-Guibert1435
BELT: +32 493097366
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 45.00 | -0.48% |
| CAC 40 | 7,937.09 | 32.60 | -0.41% |
| DAX 40 | 24,361.12 | 1.97 | -0.01% |
| Dow JONES (US) | 45,605.25 | 26.49 | -0.06% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 725.30 | 2.89% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,807.82 | 197.65 | 0.46% |
| NZX 50 Index | 13,079.50 | 114.57 | -0.87% |
| S&P 500 | 6,457.67 | 9.24 | -0.14% |
| S&P/ASX 200 | 8,972.40 | 52.00 | -0.58% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |